ROKU Roku Inc. Class A

“CYPHER” Premieres on The Roku Channel on March 19

(NASDAQ: ROKU) today announced a new scripted series, CYPHER, will premiere exclusively on The Roku Channel on March 19. CYPHER will be available for the first time to viewers in the U.S. and Canada. The show features seven one-hour episodes and will be available to viewers of The Roku Channel for free.

This press release features multimedia. View the full release here:

"CYPHER" on The Roku Channel (Graphic: Business Wire)

"CYPHER" on The Roku Channel (Graphic: Business Wire)

CYPHER puts viewers in the passenger seat alongside top FBI cryptanalyst, Will Scott (Martin Dingle Wall, Home & Away, COPS L.A.C.), who is enlisted to crack a coded document, which is revealed to be a hit list. Will soon finds himself in the crosshairs of the bad guys who want their list back. He must navigate the murky waters of loyalty and betrayal amongst an underground ring of hackers, hit men and FBI agents - all as the clock ticks in pursuit of the latest targets.

“Roku is a pioneer in TV streaming with millions of engaged users,” said executive producer and showrunner Zeus Zamani, continuing that “The Roku Channel is a premier destination for streaming entertainment because of the scale and diversity of its audience.” Producer Justin Jones adds, “We are absolutely thrilled that viewers in the U.S. and Canada will get to see CYPHER for the first time on The Roku Channel.”

As the home for both free and premium entertainment on the Roku® platform, The Roku Channel delivers thousands of titles, including free movies and TV episodes. In Q4 2020, usage of The Roku Channel grew nearly twice as fast as the overall platform and reached U.S. households with an estimated 63 million people, up more than 100% year-over-year.

“As The Roku Channel continues to grow, we’re constantly looking for ways to elevate the streaming experience for our viewers and get them to great entertainment easily and for free,” said Sweta Patel, Vice President of Engagement Growth Marketing, at Roku. “Because of The Roku Channel’s incredible reach, CYPHER has the ability to be streamed by millions of engaged viewers. We are excited to license this content exclusively for our U.S. and Canadian audiences and premiere it on The Roku Channel.”

CYPHER, produced by Aroma Studios & United Bros., stars Martin Dingle Wall as skilled cryptanalyst Will Scott, Jaclyn Hales (Mosaic, Christmas Eve) as Claire, a mysterious woman who offers to protect and help Will, Mary Helen Schmidt (She is Mine) as Will’s ex-wife Leah, Lauren Gravitt as Will’s daughter, Brian Krause (Charmed) as the FBI’s head of the case Robert, John Reardon (Hudson & Rex) as Antoine, Eve Mauro (Age of the Living Dead, Dystopia) as respected FBI agent Reese, and John J. Jordan as Andre, Reese’s partner. The series was created and directed by Majdi Smiri with Tamer Mortada, Walid Sabry, Steve Chicorel, & Kelly Mi Li also serving as executive producers.

The Roku Channel’s diverse lineup features more than 40,000 free movies and programs and 165+ free live linear television channels. In addition to the Roku platform, The Roku Channel is also available on Web, iOS and Android devices, Amazon Fire TV and select Samsung TVs and can be accessed internationally in the U.S., Canada and the U.K.

For more information, visit .

About Roku, Inc.

Roku pioneered streaming to the TV. We connect users to the streaming content they love, enable content publishers to build and monetize large audiences, and provide advertisers with unique capabilities to engage consumers. Roku streaming players and TV-related audio devices are available in the U.S. and in select countries through direct retail sales and licensing arrangements with service operators. Roku TV™ models are available in the U.S. and in select countries through licensing arrangements with TV brands. Roku is headquartered in San Jose, Calif. U.S.A.

This press release contains “forward-looking” statements that are based on our beliefs and assumptions and on information currently available to us on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to the content, benefits, features and availability of CYPHER on The Roku Channel; and the features, benefits, growth and reach of The Roku Channel and the Roku platform. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Important factors that could cause our actual results to differ materially are detailed from time to time in the reports Roku, Inc. files with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2020. Copies of reports filed with the SEC are posted on Roku’s website and are available from Roku without charge.

Roku is a registered trademark of Roku, Inc. in the U.S. and in other countries. Trade names, trademarks and service marks of other companies appearing in this press release are the property of their respective holders.

EN
11/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Roku Inc. Class A

Roku Inc: 1 director

A director at Roku Inc sold 25,000 shares at 82.424USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
HURN HURON CONSULTING GROUP INC.
GME GAMESTOP CORP. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BZH BEAZER HOMES USA INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
INOD INNODATA
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
CVCO CAVCO INDUSTRIES INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ROKU ROKU INC. CLASS A
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
PLTR PALANTIR TECHNOLOGIES
VRDN VIRIDIAN THERAPEUTICS INC
IMNM IMMUNOME
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
DAWN DAY ONE BIOPHARMACEUTICALS INC
STX SEAGATE TECHNOLOGY HLDGS PLC
ATXS ASTRIA THERAPEUTICS INC
GFS GLOBALFOUNDRIES INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
APGE APOGEE THERAPEUTICS INC
SKLZ SKILLZ INC
EMBRAC B EMBRACER GROUP AB
DNTH DIANTHUS THERAPEUTICS INC
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
Alicia Reese ... (+3)
  • Alicia Reese
  • Kade Barr
  • Matthew McCartney

ResearchPool Subscriptions

Get the most out of your insights

Get in touch